G894T Polymorphism of
            <i>eNOS</i>
            Gene is a Predictor of Response to Combination of Inhaled Corticosteroids with Long-Lasting β
            <sub>2</sub>
            -Agonists in Asthmatic Children

Iordanidou, Maria; Paraskakis, Emmanouil; Tavridou, Anna; Paschou, Peristera; Chatzimichael, Athanassios; Manolopoulos, Vangelis G.

doi:10.2217/pgs.12.120

Cited by 25 publications

(22 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The transcriptome is the set of ribonucleic acids in the cell , including messenger ribonucleic acid (mRNA), transfer ribonucleic acid (tRNA), ribosomal ribonucleic acid (rRNA), small nuclear ribonucleicacid (snRNA), noncoding ribonucleic acids (ncRNA), and others. These RNAs are differently expressed according to the tissue, the physiological condition, or the stage of development [ 46 ].…”

Section: Rna Sequencing (Rnaseq)mentioning

confidence: 99%

See 1 more Smart Citation

Molecular Genetics of Asthma

García¹

2016

Methods in Molecular Biology

View full text Add to dashboard Cite

Section: Rna Sequencing (Rnaseq)mentioning

confidence: 99%

“…It requires lots of resources compared to other techniques. The Data set is large and complex, the large amount of generated data makes the interpretation diffi cult, and usu ally a bioinformatic adviser is needed [ 46 ]. 7 From RNA-seq reads to differential expression results.…”

Section: Advantages and Limitations Of Rnaseqmentioning

confidence: 99%

Molecular Genetics of Asthma

García¹

2016

Methods in Molecular Biology

View full text Add to dashboard Cite

“…Only one study has evaluated a pathway gene (NOS3) with long-acting b 2 -agonists but the outcome was bronchodilator response over 1 year, not desensitization effects or exacerbation risk [126]. In this preliminary study of 81 children with asthma, carriers of the variant allele, Thr (Gly894Thr) had a greater lung function response compared with homozygotes (10 --20% vs 2%, p = 0.001) while on inhaled corticosteroid therapy plus long-acting b 2 -agonist.…”

Section: Gene--gene Interactions and Pathway Pharmacogenomicsmentioning

confidence: 99%

Pharmacogenomics of long-acting β₂-agonists

Blake

Lima

2015

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

show abstract

“…Thus, genetic variants in ARG1 and ARG2 may determine airway smooth muscle relaxation in response to an inhaled beta agonist [61]. In addition, the gene for endothelial nitric oxide synthase ( NOS3 ) contains a coding SNP, Asp 298 Glu, that has been associated with lung function response to LABA and ICS combination therapy in recent preliminary study of 81 asthmatic children [62]. …”

Section: Beta2-adrenergic Receptor Pathwaymentioning

confidence: 99%

Pharmacogenetics and the Development of Personalized Approaches for Combination Therapy in Asthma

Miller

Ortega

2013

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

Asthma is a common, chronic disease of the airways that is treated with a combination of different therapies. The combination of LABA and ICS therapy results in a synergistic interaction that is efficacious in improving asthma symptom control; however, genetic variation has the potential to alter therapeutic efficacy. Both agents mediate complex molecular pathways consisting of gene variation that has been investigated with the analysis of candidate genes in the β2-adrenergic receptor and glucocorticoid pathway. These pharmacogenetic studies have been limited to retrospective analyses of clinical trial cohorts and a small number of prospective, genotype-stratified trials. More recently, genome-wide association studies in combination with replication in additional cohorts and in vitro cell-based models have been used to identify novel pathway-related pharmacogenetic variations. This review of the pharmacogenetics of the β2-adrenergic receptor and glucocorticoid pathways highlights the genotypic effects of variation in multiple genes from interacting pathways which may contribute to differential responses to inhaled beta agonists and glucocorticoids. As our understanding of these genetic mechanisms improves, panels of biomarkers may be developed to determine which combination therapies are the most effective with the least risk to an individual asthma patient. Before we can usher in an era of personalized medicine for asthma, it is first important to improve our ability to analyze large volumes of genetic data in large clinical trial cohorts using a combination of study designs, analytical methods, and in vitro functional studies.

show abstract

G894T Polymorphism of eNOS Gene is a Predictor of Response to Combination of Inhaled Corticosteroids with Long-Lasting β ₂ -Agonists in Asthmatic Children

Abstract: The G894T polymorphism was associated with response to ICS and may serve as a useful pharmacogenetic marker of response to ICS plus LABAs in asthmatic children.

Cited by 25 publications

References 33 publications

Molecular Genetics of Asthma

Molecular Genetics of Asthma

Pharmacogenomics of long-acting β₂-agonists

Pharmacogenetics and the Development of Personalized Approaches for Combination Therapy in Asthma

Contact Info

Product

Resources

About

G894T Polymorphism of eNOS Gene is a Predictor of Response to Combination of Inhaled Corticosteroids with Long-Lasting β 2 -Agonists in Asthmatic Children

Abstract: The G894T polymorphism was associated with response to ICS and may serve as a useful pharmacogenetic marker of response to ICS plus LABAs in asthmatic children.

Cited by 25 publications

References 33 publications

Molecular Genetics of Asthma

Molecular Genetics of Asthma

Pharmacogenomics of long-acting β2-agonists

Pharmacogenetics and the Development of Personalized Approaches for Combination Therapy in Asthma

Contact Info

Product

Resources

About

G894T Polymorphism of eNOS Gene is a Predictor of Response to Combination of Inhaled Corticosteroids with Long-Lasting β ₂ -Agonists in Asthmatic Children

Pharmacogenomics of long-acting β₂-agonists